NEXGARD SPECTRA 150 MG 30 MG VETERINARY

Država: Izrael

Jezik: angleščina

Source: Ministry of Health

Kupite ga zdaj

Prenos Navodilo za uporabo (PIL)
24-10-2023
Prenos Lastnosti izdelka (SPC)
24-10-2023

Aktivna sestavina:

AFOXOLANER; MILBEMYCIN OXIME

Dostopno od:

BEIT-EREZ HAVAT MILATIN LTD

Farmacevtska oblika:

CHEWABLE TABLETS

Sestava:

AFOXOLANER 150 MG; MILBEMYCIN OXIME 30 MG

Pot uporabe:

PER OS

Tip zastaranja:

Not required

Izdeluje:

BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Terapevtske indikacije:

For the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (Dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (L5) and adults of Angiostrongylus vasorum) and/or treatment of gastrointestinal nematode infestations is indicated.Treatment of flea infestations (Ctenocephalides felis and C. canis) in dogs for 5 weeks.Treatment of tick infestations (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) in dogs for 4 weeks.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.Treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum, Ancylostoma braziliense and Ancylostoma ceylanicum) and whipworm (Trichuris vulpis).Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum) with monthly administration.Treatment of demodicosis (caused by Demodex canis).Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

Datum dovoljenje:

2022-09-30

Navodilo za uporabo

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Preberite celoten dokument
                                
                            

Lastnosti izdelka

                                Page 1 of 6
VETERINARY PHYSICIAN’S PRESCRIBING INFORMATION
NEXGARD SPECTRA VETERINARY
1. TRADE NAME OF MEDICINAL PRODUCT
NEXGARD SPECTRA 9 MG / 2 MG VETERINARY – chewable tablets for dogs
2–3.5 kg
NEXGARD SPECTRA 19 MG / 4 MG VETERINARY – chewable tablets for dogs
>3.5–7.5 kg
NEXGARD SPECTRA 38 MG / 8 MG VETERINARY – chewable tablets for dogs
>7.5–15 kg
NEXGARD SPECTRA 75 MG / 15 MG VETERINARY – chewable tablets for dogs
>15–30 kg
NEXGARD SPECTRA 150 MG / 30 MG VETERINARY – chewable tablets for
dogs >30–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains:
ACTIVE SUBSTANCES:
NEXGARD SPECTRA VETERINARY
AFOXOLANER (MG)
MILBEMYCIN OXIME
(MG)
chewable tablets for dogs 2–3.5 kg
9.375 mg
1.875 mg
chewable tablets for dogs >3.5–7.5 kg
18.75 mg
3.75 mg
chewable tablets for dogs >7.5–15 kg
37.50 mg
7.50 mg
chewable tablets for dogs >15–30 kg
75.00 mg
15.00 mg
chewable tablets for dogs >30–60 kg
150.00 mg
30.00 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets
Mottled red to reddish brown, circular shaped (tablets for dogs
2–3.5 kg) or rectangular shaped
(tablets for dogs >3.5–7.5 kg, tablets for dogs >7.5–15 kg,
tablets for dogs >15–30 kg and tablets
for dogs >30-60 kg).
4. CLINICAL PARTICULARS
4.1 TARGET SPECIES: Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES:
-
For the treatment of flea and tick infestations in dogs when the
concurrent prevention of
heartworm disease (_Dirofilaria immitis_ larvae), angiostrongylosis
(reduction in level of immature
adults (L5) and adults of _Angiostrongylus vasorum_) and/or treatment
of gastrointestinal
nematode infestations is indicated.
-
Treatment of flea infestations (_Ctenocephalides felis_ and _C.
canis_) in dogs for 5 weeks.
-
Treatment of tick infestations (_Dermacentor reticulatus, Ixodes
ricinus, Rhipicephalus _
_sanguineus_) in dogs for 4 weeks.
-
Fleas and ticks must attach to the host and commence feeding in order
to be exposed to the
active substance.

                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Navodilo za uporabo Navodilo za uporabo arabščina 24-10-2023
Navodilo za uporabo Navodilo za uporabo hebrejščina 24-10-2023